A case of ustekinumab-induced sclerouveitis

PURPOSE: Biologics have proven to be essential therapeutic agents in immune-mediated systemic diseases. Ophthalmologic adverse effects have been reported in the use of more traditional agents, such as TNF-α inhibitors, but there are limited data on ocular side effects associated with the newer gener...

Descripción completa

Detalles Bibliográficos
Autores principales: Godwin, Kristen S., Mathai, Mariam, Do, Brian K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819278/
https://www.ncbi.nlm.nih.gov/pubmed/35146201
http://dx.doi.org/10.1016/j.ajoc.2022.101331
_version_ 1784646025038790656
author Godwin, Kristen S.
Mathai, Mariam
Do, Brian K.
author_facet Godwin, Kristen S.
Mathai, Mariam
Do, Brian K.
author_sort Godwin, Kristen S.
collection PubMed
description PURPOSE: Biologics have proven to be essential therapeutic agents in immune-mediated systemic diseases. Ophthalmologic adverse effects have been reported in the use of more traditional agents, such as TNF-α inhibitors, but there are limited data on ocular side effects associated with the newer generation of biologics. OBSERVATIONS: In this report, we present a case of a suspected ustekinumab-associated recurrent sclerouveitis. CONCLUSIONS: To the best of our knowledge, this is the first reported case of this type seen with ustekinumab injections. Our goal is to add to the existing literature in order to better understand the mechanism and management of this condition.
format Online
Article
Text
id pubmed-8819278
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88192782022-02-09 A case of ustekinumab-induced sclerouveitis Godwin, Kristen S. Mathai, Mariam Do, Brian K. Am J Ophthalmol Case Rep Case Report PURPOSE: Biologics have proven to be essential therapeutic agents in immune-mediated systemic diseases. Ophthalmologic adverse effects have been reported in the use of more traditional agents, such as TNF-α inhibitors, but there are limited data on ocular side effects associated with the newer generation of biologics. OBSERVATIONS: In this report, we present a case of a suspected ustekinumab-associated recurrent sclerouveitis. CONCLUSIONS: To the best of our knowledge, this is the first reported case of this type seen with ustekinumab injections. Our goal is to add to the existing literature in order to better understand the mechanism and management of this condition. Elsevier 2022-01-31 /pmc/articles/PMC8819278/ /pubmed/35146201 http://dx.doi.org/10.1016/j.ajoc.2022.101331 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Godwin, Kristen S.
Mathai, Mariam
Do, Brian K.
A case of ustekinumab-induced sclerouveitis
title A case of ustekinumab-induced sclerouveitis
title_full A case of ustekinumab-induced sclerouveitis
title_fullStr A case of ustekinumab-induced sclerouveitis
title_full_unstemmed A case of ustekinumab-induced sclerouveitis
title_short A case of ustekinumab-induced sclerouveitis
title_sort case of ustekinumab-induced sclerouveitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819278/
https://www.ncbi.nlm.nih.gov/pubmed/35146201
http://dx.doi.org/10.1016/j.ajoc.2022.101331
work_keys_str_mv AT godwinkristens acaseofustekinumabinducedsclerouveitis
AT mathaimariam acaseofustekinumabinducedsclerouveitis
AT dobriank acaseofustekinumabinducedsclerouveitis
AT godwinkristens caseofustekinumabinducedsclerouveitis
AT mathaimariam caseofustekinumabinducedsclerouveitis
AT dobriank caseofustekinumabinducedsclerouveitis

Ejemplares similares